Naloxone
نالوکسان
🧪 VariousOpioid antagonist (antidote)
Market / country: 🇺🇸 USA
Narcan (US)
🧮 Dose calculator
Opioid overdose · Regimen source: FDA Naloxone inj. · Dosage and Administration
- • Repeat every 2–3 min. If no response after 10 mg, question the diagnosis. If no IV access: IM or SC. FDA Naloxone inj. · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to naloxone. FDA Naloxone inj. · Contraindications
Warnings
- • Precipitates acute withdrawal in opioid-dependent patients; its effect can be shorter than some opioids, so keep the patient monitored. FDA Naloxone inj. · Warnings
Formulations
- 1 mg/mL (2 mg/2 mL) prefilled syringe — injection 🇺🇸 USA FDA Naloxone inj. · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Darooyab: category C — only if benefit outweighs risk. Darooyab · G-1969/Naloxone — مصرف در بارداری
“مصرف در بارداری نالوکسان گروه C در شرايط خاص و نظارت ويژه پزشك قابل استفاده است:”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Naloxone inj. · Precautions/Warnings – Nursing Mothers
“Because many drugs are excreted in human milk, caution should be exercised when naloxone is administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Naloxone inj. · Pediatric Use
“Naloxone hydrochloride injection, USP may be administered intravenously, intramuscularly or subcutaneously in children and neonates to reverse the effects of opiates.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Naloxone inj. · Geriatric Use
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA213209
- DailyMed (FDA label)FDA Naloxone inj.
- MedlinePlus (NIH)Naloxone InjectionNaloxone Nasal Spray
- WHO ATC/DDDV03AB15
- Darooyab (Iran)Naloxone
🇮🇷 Registered in Iran Darooyab · G-1969/Naloxone
Dosage forms with Iranian generic codes, per Darooyab.
- 01341 · NALOXONE HCL 0.4MG/1ML AMP · آمپول نالوکسان هیدروکلراید ۰٫۴ میلیگرم / ۱ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Naloxone inj. · How SuppliedFDA Naloxone inj. · Dosage and AdministrationFDA Naloxone inj. · Usage in ChildrenFDA Naloxone inj. · ContraindicationsFDA Naloxone inj. · WarningsFDA Naloxone inj. · Precautions/Warnings – Nursing MothersFDA Naloxone inj. · Pediatric UseFDA Naloxone inj. · Geriatric UseFDA Naloxone inj. · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1969/NaloxoneDarooyab · G-1969/Naloxone — مصرف در بارداری
- Clinical review⚠ Unverified